The digital press release with multimedia content can be accessed here:
Basel, August 5, 2020 Novartis today announced that The New England Journal of Medicine (NEJM) published the positive results from the ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab (OMB157) 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with relapsing forms of multiple sclerosis (RMS). Both studies met the primary endpoints where ofatumumab showed a significant reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR)1.
ASCLEPIOS I and II demonstrate the efficacy and safety of ofatumumab and its potential to become a first-choice treatment option that offers RMS patients the flexibility as they continue to live their lives, said Krishnan Ramanathan, Neuroscience Global Program Head at Novartis. Ofatumumab is a testament to our commitment to advance science and investigate potential treatments that reimagine care and address significant unmet needs at all parts of the RMS journey.
Results from the ASCLEPIOS I and II studies showed that compared with teriflunomide, ofatumumab:
The ASCLEPIOS studies found that ofatumumab produced a significant reductionin new inflammation,as well as fewerclinical relapses and progression events, said Professor Stephen L. Hauser, Director of the UCSF Weill Institute for Neurosciences and co-chair of the steering committee for the ASCLEPIOS I and II studies. A separate post hoc analysis demonstrated thatnearly 9 out of 10 patients experienced no evidence of disease activity in the second year of treatment4. Ofatumumabrepresents a potential new option for RMS patients withgreater efficacy compared to teriflunomide,acomparable safety profile, and the convenience of once monthly self-administration withouttheneed for infusions."
These data were published in the August 6, 2020 issue of The New England Journal of Medicine.
In February, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) accepted the companys Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of relapsing forms of multiple sclerosis in adults. If approved, ofatumumab will be the first B-cell therapy that can be self-administered at home and has the potential to become a first-choice treatment for use in RMS patients.
Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021. Novartis is committed to bringing ofatumumab to patients worldwide and additional regulatory filings are currently underway.
About ofatumumab Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) in development for RMS that is self-administered by a once-monthly injection, delivered subcutaneously1,3. As shown in preclinical studies, ofatumumab is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion5. The selective mechanism of action and subcutaneous administration of ofatumumab allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and preclinical studies have shown that it may preserve the B-cells in the spleen6. Once-monthly dosing of ofatumumab also allows faster repletion of B-cells and offers flexibility7. Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline. Novartis obtained rights for ofatumumab from GlaxoSmithKline in all indications, including RMS, in December 20158.
About ASCLEPIOS I and II studies The ASCLEPIOS I and II studies are twin, identical design, flexible duration (up to 30 months), double-blind, randomized, multi-center Phase III studies evaluating the safety and efficacy of ofatumumab 20 mg monthly subcutaneous injections versus teriflunomide 14 mg oral tablets taken once daily in adults with RMS. The ASCLEPIOS I and II studies enrolled 1882 patients with MS, between the ages of 18 and 55 years, with an Expanded Disability Status Scale (EDSS) score between 0 and 5.51. The studies were conducted in over 350 sites in 37 countries9. Ofatumumab demonstrated a significant reduction in ARR by 51% (0.11 vs 0.22) and 58% (0.10 vs 0.25) compared with teriflunomide (P<.001 in both studies) in ASCLEPIOS I and II, respectively (primary endpoint). Ofatumumab also showed a relative risk reduction of 34% (P=.002) in 3-month CDW and 32% (P=.01) in 6-month CDW compared with teriflunomide in a pre-specified meta-analysis, as defined in ASCLEPIOS1.
Story continues
Ofatumumab showed significant reduction of both Gd+ T1 lesions and new or enlarging T2 lesions. It significantly reduced the mean number of both Gd+ T1 lesions (97% and 94% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) and new or enlarging T2 lesions (82% and 85% relative reduction in ASCLEPIOS I and II, respectively, both P<.001) vs teriflunomide1. Ofatumumab demonstrated that it lowered NfL levels in serum at the first assessment at Month 3 compared with teriflunomide. There was no difference in slope of brain volume change from baseline between treatments. In a measure of 6-month CDI events, a favorable trend for ofatumumab was seen but this did not reach significance vs teriflunomide1.
Ofatumumab had a similar safety profile to teriflunomide, with the frequency of serious infections and neoplasms also being similar across both treatment groups1. Injection-related reactions, nasopharyngitis, headache, injection-site reactions, upper respiratory tract infection and urinary tract infection were the most commonly observed adverse events across both treatment groups, occurring in 10% of patients1.
Overall, ofatumumab, a fully-human antibody targeting CD20 positive B-cells, delivered superior efficacy and demonstrated a safety profile with infection rates similar to teriflunomide1.
About Multiple Sclerosis Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS characterized by myelin destruction and axonal damage of the brain, optic nerves and spinal cord10. MS, which affects approximately 2.3 million people worldwide11, can be characterized into four main types of MS: clinically isolated syndrome (CIS), relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS)12. The various forms of MS can be distinguished based on whether a patient experiences relapses (clearly defined acute inflammatory attacks of worsening neurological function), and/or whether they experience progression of neurologic damage and disability from the onset of the disease10.
Novartis in Neuroscience Novartis has a strong ongoing commitment to neuroscience and to bringing innovative treatments to patients suffering from neurological conditions where there is a high unmet need. We are committed to supporting patients and physicians in multiple disease areas, including MS, migraine, Alzheimer's disease, Parkinson's disease, epilepsy and attention deficit hyperactivity disorder, and have a promising pipeline in MS, Alzheimer's disease, spinal muscular atrophy and specialty neurology.
Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Dr. Hausers statements reflect his professional opinion and not necessarily the views of The Regents of the University of California. Nothing in his statements shall be construed to imply any support or endorsement of Novartis, or any of its products, by The Regents of the University of California.
About Novartis Novartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews For Novartis multimedia content, please visithttps://www.novartis.com/news/media-library For questions about the site or required registration, please contact media.relations@novartis.com
References 1. Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 2020;383:546-57.https://www.nejm.org. 2. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206(2):16571. 3. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study. Poster presentation at: ACTRIMS; February 2020; West Palm Beach, FL. 4. Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: Analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. Eur J Neurol. 2020;27(S1). 5. Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20 antibody achieving potent B-cell depletion through binding a distinct epitope. Poster presentation at: ECTRIMS; September 2016; London, UK. 6. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: ECTRIMS; September 2016; London, UK. 7. Savelieva M, Kahn J, Bagger M, et al. Comparison of the B-Cell recovery time following discontinuation of anti-CD20 therapies. ePoster presentation at: ECTRIMS; October 2017; Paris, FR. 8. Genmab Press Release: Genmab announces completion of agreement to transfer remaining ofatumumab rights. December 21, 2015. Accessed June 17, 2020. https://ir.genmab.com/static-files/9d491b72-bb0b-4e46-a792-dee6c29aaf7d 9. Kappos L, Bar-Or A, Comi G, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis: baseline characteristics of two pivotal phase 3 trials (ASCLEPIOS I and ASCLEPIOS II). Poster presentation at: ECTRIMS; October 2018; Berlin, Germany. 10. Guthrie E. Multiple sclerosis: a primer and update. Adv Studies Pharm. 2007;4(11):313-317. 11. Multiple Sclerosis International Federation. Atlas of MS 2013-Mapping Multiple Sclerosis Around the World. Accessed July 10, 2020. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf 12. National MS Society. Types of MS. Accessed May 20, 2020. https://www.nationalmssociety.org/What-is-MS/Types-of-MS
# # #
Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com
- Rally for Multiple Sclerosis Treatment Funding [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- Breakthrough Multiple Sclerosis Treatment? [Last Updated On: May 8th, 2011] [Originally Added On: May 8th, 2011]
- Multiple Sclerosis Treatment - Mayo Clinic [Last Updated On: May 11th, 2011] [Originally Added On: May 11th, 2011]
- Tracy Macchia: Controversial MS Treatment [Last Updated On: May 14th, 2011] [Originally Added On: May 14th, 2011]
- What is Multiple Sclerosis [Last Updated On: May 19th, 2011] [Originally Added On: May 19th, 2011]
- MS Multiple Sclerosis treatment testimonial from Sanoviv Medical Institute [Last Updated On: May 20th, 2011] [Originally Added On: May 20th, 2011]
- Patient with progressive ms(paraplegia) Fmr treatment 1/4 [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- New Jersey Multiple Sclerosis Treatment with Chiropractic Care [Last Updated On: May 23rd, 2011] [Originally Added On: May 23rd, 2011]
- MS Cure - Progression [Last Updated On: June 2nd, 2011] [Originally Added On: June 2nd, 2011]
- CCSVI UK Multiple Sclerosis Liberation Treatment [Last Updated On: June 2nd, 2011] [Originally Added On: June 2nd, 2011]
- Stem Cell Therapy MS: Sam Harrell and The Superbowl [Last Updated On: June 3rd, 2011] [Originally Added On: June 3rd, 2011]
- Holly Huber on Recovery: Stem Cell Therapy for Multiple Sclerosis Community Outreach Dallas, TX 2011 [Last Updated On: June 8th, 2011] [Originally Added On: June 8th, 2011]
- MS treatment sees early success [Last Updated On: June 9th, 2011] [Originally Added On: June 9th, 2011]
- CCSVI Possible cure for Multiple sclerosis [Last Updated On: June 10th, 2011] [Originally Added On: June 10th, 2011]
- MS Cure - Introduction to stem cell bone marrow transplant in Australia [Last Updated On: June 11th, 2011] [Originally Added On: June 11th, 2011]
- (Multiple Sclerosis Cure) Change Your Thinking? (Multiple Sclerosis Cure) [Last Updated On: June 12th, 2011] [Originally Added On: June 12th, 2011]
- Essiac cancer treatment herbal tincture, Ms Caisse...from The Secrets of Eden [Last Updated On: June 12th, 2011] [Originally Added On: June 12th, 2011]
- MS walking treatment breakthrough [Last Updated On: June 14th, 2011] [Originally Added On: June 14th, 2011]
- multiple sclerosis natural treatment | Kathy Canada Testimonial [Last Updated On: June 18th, 2011] [Originally Added On: June 18th, 2011]
- CCSVI Surgery India - Liberation Procedure Multiple Sclerosis Treatment in India [Last Updated On: June 29th, 2011] [Originally Added On: June 29th, 2011]
- XCell-Center MS CCSVI Liberation Angioplasty Treatment Results E.Schuurman 18_01_11 [Last Updated On: July 1st, 2011] [Originally Added On: July 1st, 2011]
- MS Cure - 7PM Project Carmel Turner MS Stem Cell Treatment [Last Updated On: July 9th, 2011] [Originally Added On: July 9th, 2011]
- MS Update! Tysabri or Gilenya? [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- What causes BSE, CJD [Last Updated On: July 15th, 2011] [Originally Added On: July 15th, 2011]
- Kath Bartlett, MS, LAc Balance Method Acupuncture [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- MS Cure - 730 report ben leahy carmel turner ms stem cell treatment [Last Updated On: July 17th, 2011] [Originally Added On: July 17th, 2011]
- CCSVI LIberation Treatment Tokuda [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- FOX News Interview on the O'Reilly Factor - Treatment of Women in Islam [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- CCSVI treatment bloopers holy crap [Last Updated On: July 18th, 2011] [Originally Added On: July 18th, 2011]
- Tarah's CCSVI Venoplasty. Dr McGuckin Explaining procedure findings [Last Updated On: July 19th, 2011] [Originally Added On: July 19th, 2011]
- Cancer Cure: The One-Minute Cure For Cancer, MS [Last Updated On: July 24th, 2011] [Originally Added On: July 24th, 2011]
- Not Ready to Cheer CCSVI Trials [Last Updated On: July 29th, 2011] [Originally Added On: July 29th, 2011]
- New Oral Treatment for MS [Last Updated On: July 30th, 2011] [Originally Added On: July 30th, 2011]
- 27/07/2011 - MS patients seek controversial treatment [Last Updated On: August 1st, 2011] [Originally Added On: August 1st, 2011]
- MS Cure - 11 I am still walking [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- Upcoming Treatments for MS - Pt 1 -MSRA Public Lecture - Dr Suzanne Hodgkinson [Last Updated On: August 10th, 2011] [Originally Added On: August 10th, 2011]
- Stem Cells for MS Community Outreach: Patient Judi Lecoq - Dallas, TX 2011 [Last Updated On: August 18th, 2011] [Originally Added On: August 18th, 2011]
- Stem Cell Treatment for Multiple Sclerosis - Community Outreach, San Diego: David Oliver [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- New Study Tests Possible Treatment for MS [Last Updated On: August 25th, 2011] [Originally Added On: August 25th, 2011]
- Professor Dimitrios Karussis: Treating MS [Last Updated On: August 26th, 2011] [Originally Added On: August 26th, 2011]
- walking with MS before CCSVI treatment.wmv [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Suzy Cohen Discusses The Liberation Treatment for MS [Last Updated On: September 14th, 2011] [Originally Added On: September 14th, 2011]
- Multiple Sclerosis MS People - Amazing New Treatment [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Multiple Sclerosis Alternative Treatment [Last Updated On: September 17th, 2011] [Originally Added On: September 17th, 2011]
- CLEAR scoliosis treatment, Dr. Culpepper (MS) [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- Liberation treatment for MS [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- 44b - My Lyme disease and rheumatoid arthritis journey - Miraculous CCSVI treatment for MS sufferers [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- A Closer Look at Gilenya - The First Oral Treatment for MS [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Unequal Treatment Drives Disability Rights Movement [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Multiple Sclerosis - The Nebraska Medical Center [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Testimonial for CCSVI Treatment Excel Heart Center Mexico -- Tanya Reay [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Current thinking on what causes MS - Pt 1 - MSRA Public Lecture -Prof Graeme Stewart [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Current and emerging therapies in MS - Part 02 (How do these treatments work?) [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- MS Richard Humphries before and after treatment for Multiple Sclerosis with stem cells [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- Matthew - CCSVI and his Liberation Treatment [Last Updated On: October 8th, 2011] [Originally Added On: October 8th, 2011]
- Multiple Sclerosis - Myelin Repair - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- MS Auto Immune vs CCSVI Treatment Simple Pictures by Berukoff - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- New Promising Treatment for Those Living with Multiple Sclerosis - Video [Last Updated On: October 29th, 2011] [Originally Added On: October 29th, 2011]
- Stem cells to treat MS - Pt 2 - MSRA Public Lecture - A/Prof Richard Burt - Video [Last Updated On: October 30th, 2011] [Originally Added On: October 30th, 2011]
- New hope for treating multiple sclerosis - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- CCSVI Multiple sclerosis Breakthrough/cure - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- Inhuman Treatment of Wheelchair bound Multiple Sclerosis Patient in Canadian Care Home - Video [Last Updated On: November 9th, 2011] [Originally Added On: November 9th, 2011]
- MS treatment movie Cells4health.mp4 - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- Racing to the Cure for MS: Myelin Repair Foundation Celebrates MS Awareness Week - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- [Symptoms of Multiple Sclerosis] - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Multiple Sclerosis Treated with Adult Stem Cells - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Stem cells to treat MS - Pt 1 - MSRA Public Lecture - A/Prof Richard Burt - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- Multiple Sclerosis A Natural Treatment - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- My MS and Stem Cell Treatment - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- CCSVI Liberation News Reports - Video [Last Updated On: November 20th, 2011] [Originally Added On: November 20th, 2011]
- Stem Cells for MS Community Outreach: Patient Sam Harrell - Dallas, TX 2011 - Video [Last Updated On: November 21st, 2011] [Originally Added On: November 21st, 2011]
- Arthur S13 E2-1 - The Silent Treatment - Video [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- Holly Huber on Recovery: Stem Cell Therapy for Multiple Sclerosis Community Outreach San Diego CA - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- CCSVI - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- My Sister's Experience with Liberation Treatment for Multiple Sclerosis PART 2/2 - Video [Last Updated On: December 5th, 2011] [Originally Added On: December 5th, 2011]
- Multiple Sclerosis -- Treatment LDN story - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- ABC News - Multiple Sclerosis effectively treated by a new acoustic medical device. - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- MS Patient After Stem Cell Therapy - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- Multiple Sclerosis - Video [Last Updated On: December 12th, 2011] [Originally Added On: December 12th, 2011]
- Journey of Connective Tissue, Autoimmune disease, steroid treatment updates. - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]